# SPECIALTY QUANTITY LIMIT PROGRAM

## LYNPARZA (olaparib)

### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

### **II. COVERED QUANTITIES**

Medication	Standard Limit	FDA-recommended dosing
Lynparza (olaparib) 100 mg tablets	120 per 30 days	Ovarian cancer, breast cancer, and pancreatic
Lynparza (olaparib) 150 mg tablets	120 per 30 days	cancer: 300 mg orally twice daily Dose modifications due to adverse reactions, drug interactions, or renal
		impairment: 100 mg orally twice daily- 250 mg orally twice daily

### III. REFERENCES

1. Lynparza® Tablets [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; December 2019.

Specialty Quantity Limit Lynparza 2237-H P2019b.docx

© 2019 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

